Q-omics provides the consensus-scored CDH7 profile across patient tissues and cancer cell-line models. CDH7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CDH7 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, CDH7 RNA expression shows 11,453 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, BRCA, and TGCT as cancer lineages where CDH7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH7 survival associations across molecular data types. CDH7 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH7 RNA expression–survival associations across cancer types. High CDH7 expression shows unfavorable associations in THCA, UCEC and COAD, but favorable associations in BRCA, READ and LGG. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for CDH7 RNA expression.
This table summarizes CDH7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CDH7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH7 shows lower tumor expression in KIRP and LUSC and higher tumor expression in BRCA, COAD, PRAD and LUAD. The BRCA box plot shows higher CDH7 RNA expression in tumor versus normal tissue (log2 FC = +0.270, t-test p < 0.001).
This table shows molecular features associated with CDH7 in patient tissues and cancer cell lines. In patient samples, CDH7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
